1,839 results on '"Dore, Gregory J"'
Search Results
202. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study
203. Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection.
204. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort
205. Clearance of Hepatitis C Virus after Newly Acquired Infection in Injection Drug Users
206. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial
207. Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naive and -Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus
208. Chronic Hepatitis C Is Associated With Peripheral Rather Than Hepatic Insulin Resistance
209. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial
210. Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection
211. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
212. All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy
213. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications
214. Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Persons in a Randomized, Controlled Study (CAESAR)
215. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
216. Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
217. Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study
218. Disseminated Microsporidiosis Due to Septata intestinalis in Nine Patients Infected with the Human Immunodeficiency Virus: Response to Therapy with Albendazole
219. Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study.
220. Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn
221. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons
222. Prescribing of direct‐acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program
223. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis
224. Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan
225. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia
226. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study
227. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study
228. Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection
229. Infection with HIV and Hepatitis C Virus among Injecting Drug Users in a Prevention Setting: Retrospective Cohort Study
230. Polymerase Chain Reaction as Marker of Infectivity in People with Hepatitis C
231. Systematic Review of Role of Polymerase Chain Reaction in Defining Infectiousness among People Infected with Hepatitis C Virus
232. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada
233. A prospective study of hepatitis C incidence in Australian prisoners
234. Dynamics of HCV RNA levels during acute hepatitis C virus infection
235. High Efficacy of Treatment with Sofosbuvir+GS-5816 ±Riavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection: 197
236. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents
237. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia1
238. Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection
239. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response
240. Can hepatitis C virus infection be eradicated in people who inject drugs?
241. Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?
242. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa
243. Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies
244. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
245. Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort.
246. Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale‐up of direct‐acting antiviral treatment
247. Persistent symptoms up to four months after community and hospital‐managed SARS‐CoV‐2 infection
248. Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study
249. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study
250. Prevalence and risk factors for hepatitis C infection in rural north Vietnam
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.